Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

16.510
-0.780-4.51%
Volume:8.50M
Turnover:140.91M
Market Cap:43.87B
PE:11.13
High:17.200
Open:17.200
Low:16.360
Close:17.290
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:539.00M
Volume Ratio:1.49
T/O Rate:1.58%
Dividend:0.46
Dividend Rate:2.76%
EPS(LYR):1.483
ROE:6.95%
ROA:1.40%
PB:0.77
PE(LYR):11.13
PS:0.88

Loading ...

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

MT Newswires Live
·
Apr 14

Fosun Pharma receives NMPA green light for Phase I/II trials of dual-target CAR-T therapy FKC289

Bulletin Express
·
Apr 14

Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Phase I/Ii Clinical Trial of Fkc289 Injection

THOMSON REUTERS
·
Apr 14

FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News
·
Apr 14

Hong Kong Market Announcement Highlights: VGT Launches IPO with CPE Rosewood and Janchor Fund as Cornerstone Investors

Stock News
·
Apr 13

BRIEF-Shanghai Fosun Pharma Unit's Drug Registration Application For Flurbiprofen Axetil Injection Approved By NMPA

Reuters
·
Apr 10

FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization

Stock News
·
Apr 10

Shanghai Fosun Pharma - Unit's Drug Registration Application for Flurbiprofen Axetil Injection Approved by Nmpa

THOMSON REUTERS
·
Apr 10

Fosun Pharma Schedules 28 April Board Meeting to Review Q1 2026 Results

Bulletin Express
·
Apr 10

Fosun Pharmaceutical Names CFO

MT Newswires Live
·
Apr 03

Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug

MT Newswires Live
·
Apr 02

FOSUN PHARMA Subsidiary Receives Clinical Trial Approval for HLX319 Drug

Stock News
·
Apr 01

Fosun Pharmaceutical to Set Up Parallel Fund Structure

MT Newswires Live
·
Apr 01

Fosun Pharma Unit Gets China Nod for Tumor Drug Trial

MT Newswires Live
·
Mar 31

Fosun Pharma Subsidiary Secures NMPA Approval to Launch Phase I Trial of FXB0871 for Advanced Solid Tumors

Bulletin Express
·
Mar 31

BRIEF-Shanghai Fosun Pharma Announces Approval From NMPA For Clinical Trial Of FXB0871

Reuters
·
Mar 31

Shanghai Fosun Pharma - Approval From Nmpa for Clinical Trial of Fxb0871

THOMSON REUTERS
·
Mar 31

FOSUN PHARMA Reports 2025 Results: Revenue Hits 41.7B Yuan with 21.7% Net Profit Growth

Deep News
·
Mar 25

FOSUN PHARMA Shares Surge Over 5% as Annual Net Profit Climbs 21.69% to 3.37 Billion Yuan

Deep News
·
Mar 25

Stock Track | Fosun Pharma Soars 5.21% Intraday on Strong 2025 Earnings and Dividend Announcement

Stock Track
·
Mar 25